Changes brewing in the US renal anemia market, suggest reports from BioTrends
According to recent syndicated reports on the management of renal anemia in the USA, familiarity with biotechnology giant Amgen's clinical trial TREAT has increased and around 90% of nephrologists are at least somewhat familiar with the study.
Close to two-thirds report the study had led to changes or expected changes in their use of erythropoietin stimulating agents (ESAs) in chronic kidney disease non-dialysis (CKD-ND) patients; the study has also led to changes in anemia management in dialysis patients, albeit to a lesser extent. Impact appears to be on the ESA class as a whole, effecting both Amgen's Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) and Centocor Ortho Biotech's Procrit (epoetin alfa), say the reports from BioTrends.
Lower safety ratings for ESAs
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze